JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3001
Lattice Semiconductor
LSCC
$19.1B
| $2.83M | ﹤0.01% |
201,414
+60,721
| +43% | +$810K |
2016 Q4
10 quarters
|
|
|
AZUL
3002
DELISTED
Azul
AZUL
| $2.81M | ﹤0.01% |
85,410
+16,582
| +24% | +$481K |
2017 Q2
8 quarters
|
|
|
AFI
3003
DELISTED
Armstrong Flooring, Inc.
AFI
| $2.81M | ﹤0.01% |
295,699
+74,164
| +33% | +$918K |
2016 Q4
10 quarters
|
|
|
I
3004
DELISTED
INTELSAT S. A.
I
| $2.8M | ﹤0.01% |
142,317
+113,655
| +397% | +$2.2M |
2017 Q4
6 quarters
|
|
3005
TriMas Corp
TRS
$1.4B
| $2.8M | ﹤0.01% |
92,457
+2,814
| +3% | +$86.3K |
2013 Q2
24 quarters
|
|
3006
OceanFirst Financial
OCFC
$1.62B
| $2.79M | ﹤0.01% |
114,775
+5,208
| +5% | +$128K |
2013 Q2
24 quarters
|
|
|
BLUE
3007
CALL
DELISTED
bluebird bio
BLUE
| $2.79M | ﹤0.01% |
+1,737
| New | +$3M |
2019 Q2
0 quarters
|
|
|
TCRR
3008
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $2.79M | ﹤0.01% |
192,337
-6,384
| -3% | -$102K |
2019 Q1
1 quarter
|
|
|
RAD
3009
DELISTED
Rite Aid Corporation
RAD
| $2.78M | ﹤0.01% |
324,455
-936,140
| -74% | -$8.07M |
2013 Q2
24 quarters
|
|
|
WCC
3010
WESCO International
WCC
$18.7B
| $2.78M | ﹤0.01% |
54,873
-54,486
| -50% | -$2.85M |
2013 Q2
24 quarters
|
|
3011
Chesapeake Utilities
CPK
$3.23B
| $2.77M | ﹤0.01% |
29,833
+2,422
| +9% | +$224K |
2017 Q3
7 quarters
|
|
3012
Tactile Systems Technology
TCMD
$503M
| $2.77M | ﹤0.01% |
51,335
+26,792
| +109% | +$1.4M |
2017 Q4
6 quarters
|
|
3013
CALL
DaVita
DVA
$11.5B
| $2.77M | ﹤0.01% |
50,000
| – | – |
2019 Q1
1 quarter
|
|
3014
Fidelity Total Bond ETF
FBND
$27.9B
| $2.77M | ﹤0.01% |
54,272
-10
| -0% | -$503 |
2015 Q3
15 quarters
|
|
3015
Universal Corp
UVV
$1.06B
| $2.77M | ﹤0.01% |
45,875
+11,133
| +32% | +$624K |
2013 Q2
24 quarters
|
|
|
DSSI
3016
DELISTED
Diamond S Shipping Inc. Common Shares
DSSI
| $2.77M | ﹤0.01% |
235,539
+45,340
| +24% | +$561K |
2019 Q1
1 quarter
|
|
|
CEO
3017
DELISTED
CNOOC Limited
CEO
| $2.77M | ﹤0.01% |
16,148
-4,893
| -23% | -$852K |
2013 Q2
24 quarters
|
|
|
XLRN
3018
DELISTED
Acceleron Pharma
XLRN
| $2.77M | ﹤0.01% |
67,638
-6,649
| -9% | -$275K |
2017 Q3
7 quarters
|
|
|
FNHC
3019
DELISTED
FedNat Holding Company Common Stock
FNHC
| $2.76M | ﹤0.01% |
199,086
+108
| +0.1% | +$1.65K |
2016 Q4
10 quarters
|
|
3020
Rhythm Pharmaceuticals
RYTM
$6.25B
| $2.75M | ﹤0.01% |
126,835
+3,057
| +2% | +$77.2K |
2017 Q4
6 quarters
|
|
|
CRCM
3021
DELISTED
CARE.COM, INC.
CRCM
| $2.75M | ﹤0.01% |
249,964
+245,101
| +5,040% | +$3.71M |
2017 Q3
7 quarters
|
|
|
RETA
3022
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.75M | ﹤0.01% |
+30,000
| New | +$2.59M |
2019 Q2
0 quarters
|
|
|
GMS
3023
DELISTED
GMS Inc
GMS
| $2.74M | ﹤0.01% |
139,159
+128,563
| +1,213% | +$2.31M |
2016 Q4
10 quarters
|
|
3024
Toyota
TM
$220B
| $2.73M | ﹤0.01% |
22,071
+6,591
| +43% | +$804K |
2013 Q2
24 quarters
|
|
3025
Sally Beauty Holdings
SBH
$1.52B
| $2.73M | ﹤0.01% |
212,202
+3,245
| +2% | +$53K |
2015 Q4
14 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.